https://9690e.iqanda-cme.com/ 2019-06-06T23:04:49+0000 weekly 1 https://9690e.iqanda-cme.com/submit-a-question 2019-05-08T22:03:10+0000 weekly 0.8 https://9690e.iqanda-cme.com/about-iqanda-multi-specialty 2019-04-03T23:01:03+0000 weekly 0.8 https://9690e.iqanda-cme.com/multi-specialty 2019-09-07T01:23:26+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/you-have-made-the-case-for-a-call-to-action-to-treat-ldl-c-very-aggressively-in-diabetic-patients-with-known-ascvd-what-is-your-rationale-for-this-and-how-do-the-recent-rials-support-your-recommendation-to-treat-diabetics-with-ascvd-aggr 2019-04-08T05:16:55+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/within-the-context-of-the-esc-and-u-s-guidelines-for-ldl-c-reduction-which-recommend-70-mg/dl-as-a-threshold-target-how-should-we-view-the-cholesterol-landscape-between-20-mg/dl-and-70-mg/dl-in-light-of-the-odyssey-outcomes-trial 2019-04-02T00:33:33+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-should-the-lipid-specialist-approach-the-individual-with-diabetes-who-doesn-t-yet-have-ascvd 2019-04-08T05:18:47+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-is-the-profile-of-the-diabetic-patient-in-whom-the-diabetes-specialist-should-strongly-consider-the-ldl-c-lowering-and-outcome-improving-effects-of-pcsk9-inhibitors-how-do-we-risk-stratify-populations-for-secondary-prevention 2019-04-02T00:33:22+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-the-setting-of-secondary-post-acs-prevention-what-is-your-trigger-for-moving-beyond-a-statin/ezetimibe-combination-to-a-pcsk9-inhibitor 2019-04-02T00:29:19+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-is-your-analysis-of-the-two-major-cv-outcome-trials-and-from-a-mortality-end-point-perspective-in-what-way-do-mortality-outcome-end-points/results-distinguish-the-odyssey-outcomes-trial-with-alirocumab 2019-04-08T05:22:45+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/based-on-the-results-of-odyssey-outcomes-and-fourier-do-you-recommend-that-clinicians-strive-in-selected-high-risk-populations-to-lower-ldl-c-significantly-lower-than-70-mg/dl 2019-04-02T00:35:31+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-medical-cardiologist-s-perspective-which-patient-subgroups-in-your-practice-do-you-feel-represent-ideal-candidates-for-deployment-of-pcsk9-inhibitors-to-lower-ldl-c-levels-based-on-the-results-of-the-odyssey-outcomes-and-fourier-t 2019-04-02T00:49:41+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-share-with-us-a-specific-patient-who-has-had-an-acs-event-and-is-post-pci-and-how-you-optimize-cv-risk-reduction-in-the-age-of-pcsk9-mediated-ldl-c-risk-reduction-and-aggressive-ldl-c-lowering 2019-04-08T05:00:36+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-lipid-medicine-and-atherosclerosis-expert-s-perspective-when-you-look-at-the-odyssey-outcomes-and-fourier-trials-what-consistent-or-comparative-message-do-you-take-from-these-investigations-into-the-safety-and-efficacy-of-pcsk9-in 2019-04-02T00:30:15+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-your-mind-as-a-director-of-a-lipid-clinic-and-preventive-cardiology-center-how-do-you-apply-the-results-of-the-odyssey-outcomes-and-other-trials-in-terms-of-the-lack-of-safety-signals-when-lowering-ldl-c-to-levels-50-mg/dl 2019-04-08T05:41:26+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-are-your-2019-esc/eas-guidelines-going-to-be-influenced-by-recent-rcts-including-odyssey-outcomes-and-fourier 2019-04-02T00:30:08+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-lipid-medicine-specialist-s-perspective-what-would-your-approach-be-to-a-post-acs-patient-with-two-stents-and-triple-vessel-disease-whose-ldl-c-level-is-70-mg/dl 2019-04-08T05:36:20+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-paint-the-profile-of-the-post-acs-patient-with-t2d-in-whom-the-aggregate-cv-risk-exceeds-a-threshold-that-supports-a-strategy-of-pcsk9-mediated-ldl-c-reduction-in-order-to-achieve-levels-of-less-than-70-mg/dl-or-even-less-than-50 2019-04-02T00:47:58+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-a-leading-authority-in-ldl-c-mediated-cv-risk-reduction-can-you-provide-us-with-your-perspective-on-the-evidence-for-pcsk9-inhibitors-as-a-foundational-approach-for-managing-a-broad-spectrum-of-patients-with-high-risk-coronary-heart-d 2019-04-08T05:27:56+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/within-the-context-of-a-medical-cardiology-practice-especially-navigating-among-patients-with-inadequate-responses-to-ezetimibe-and/or-statin-intolerance-or-resistance-how-do-you-sequence-pcsk9-inhibitors-in-your-ldl-c-lowering-treatment 2019-04-08T05:33:47+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-the-interventional-cardiology-setting-what-percentage-of-your-patients-do-not-achieve-the-esc-lipid-guideline-goal-of-70-mg/dl-and-therefore-are-suitable-candidates-for-pcsk9-inhibition-can-you-discuss-your-patient-selection-process 2019-04-02T00:34:29+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-is-the-true-incidence-of-statin-intolerance-and-how-do-you-diagnose-it-and-what-is-your-approach-to-re-challenge-and-titration-with-other-statins-and-where-do-alirocumab-and-evolocumab-fit-into-the-statin-intolerance-treatment-plan 2019-04-02T00:30:47+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-would-your-approach-be-to-a-57-year-old-man-with-an-ldl-c-of-70-mg/dl-who-has-recently-had-an-acs-event-and-now-develops-recurrent-acs-or-a-new-stent-thrombosis-does-odyssey-outcomes-provide-any-evidence-based-guidance 2019-04-02T00:34:35+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-should-the-approach-be-in-patients-who-have-had-a-coronary-event-with-an-ldl-c-level-of-70-mg/dl-do-the-outcome-studies-with-pcsk9-inhibitors-provide-an-evidentiary-roadmap-for-this-common-situation 2019-04-02T00:54:59+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/now-with-the-publication-of-odyssey-outcomes-which-demonstrated-an-associated-all-cause-mortality-reduction-benefit-how-do-you-view-the-foundational-role-of-pcsk9-inhibitors-in-the-cv-risk-treatment-plan-for-high-risk-patient-populations 2019-04-08T05:26:19+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-an-interventional-cardiology-perspective-what-did-odyssey-outcomes-teach-us-about-the-large-subgroup-of-diabetic-patients-who-had-acs-plus-stent-insertions 2019-04-02T00:34:21+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-specific-ldl-c-related-endpoints-are-likely-to-undergo-review-and-revisions-based-on-the-publication-of-two-pcsk9-related-trials-odyssey-outcomes-and-fourier 2019-04-08T05:15:26+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-safety-perspective-how-do-you-counsel-your-patients-in-whom-you-are-beginning-pcsk9-inhibitor-therapy 2019-04-02T00:49:29+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/if-someone-is-more-than-12-months-out-after-an-acs-event-and-currently-has-a-stent-would-you-still-consider-them-to-be-eligible-for-pcsk9-therapy-to-lower-ldl-c-and-residual-cv-risk 2019-04-02T00:34:25+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/you-have-identified-the-challenges-of-accessing-pcsk9-inhibitors-for-patients-whose-cv-risk-is-genetic-vs-those-whose-clinical-course-is-characterized-by-progressive-vascular-events-how-do-you-approach-each-subset-with-respect-to-ldl-c-m 2019-04-02T00:54:30+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/since-odyssey-outcomes-demonstrated-a-reduction-in-adverse-cv-outcomes-as-well-as-a-decrease-in-associated-all-cause-mortality-in-post-acs-patients-what-is-your-view-on-treating-to-push-ldl-c-levels-to-even-lower-levels-than-the-70-mg/dl 2019-04-08T05:48:30+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-a-thrombosis-specialist-and-cardiologist-how-do-respond-to-the-recent-aha-guidelines-identifying-70-mg/dl-as-a-threshold-target-for-high-risk-patients-is-this-target-a-starting-point-or-a-stopping-point-for-your-ldl-c-lowering-goals 2019-04-02T00:35:25+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-see-the-future-of-access-affordability-and-general-utilization-of-pcsk9-inhibitors-as-a-result-of-the-price-reductions-and-results-from-cv-outcome-trials 2019-04-02T00:32:50+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/although-the-aha-guidelines-identify-a-70-mg/dl-threshold-target-for-patients-at-high-risk-for-recurrent-acs-do-you-believe-this-is-merely-a-starting-point-identifying-a-minimal-level-of-ldl-c-goal-attainment 2019-04-08T05:05:29+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-unique-aspects-with-respect-to-all-cause-mortality-outcomes-and-baseline-ldl-c-levels-were-observed-in-the-odyssey-outcomes-trial-and-how-would-you-translate-these-results-into-patient-care 2019-04-02T00:36:32+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/the-pcsk9-trials-have-confirmed-a-the-absence-of-a-j-point-curve-for-ldl-c-lowering-and-b-continuing-cv-risk-reduction-even-when-lowering-ldl-c-from-100mg/dl-to-30mg/dl-in-light-of-this-how-should-the-lipid-specialist-deploy-pcsk9-inhibi 2019-04-02T00:55:08+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-the-subpopulation-of-high-risk-patients-individuals-with-post-acs-patients-with-diabetes-post-pci-and-others-is-there-enough-compelling-evidence-from-the-pcsk9-trials-that-the-ldl-hypothesis-is-a-proven-fact 2019-04-08T05:45:07+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-recommend-managing-the-patient-who-has-a-major-cv/thrombotic-event-a-recent-mi-who-is-on-a-statin-and-has-an-ldl-c-level-of-60-70-mg/dl-how-does-the-odyssey-outcome-trial-and/or-ivus-studies-help-you-assess-the-role-of-a-pcsk9 2019-04-02T00:48:17+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/based-on-odyssey-outcomes-which-patients-in-an-interventional-cardiology-practice-do-you-believe-will-benefit-most-from-pcsk9-inhibition 2019-04-02T00:32:40+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-exactly-did-you-and-your-colleagues-model-the-pharmacoeconomic-effectiveness-of-alirocumab-based-on-the-actual-results-of-the-odyssey-outcomes-trial 2019-04-02T00:49:45+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-shown-in-the-odyssey-outcomes-trial-alirocumab-lowers-lp-a-fourier-also-demonstrated-similar-results-with-evolocumab-what-are-the-implications-of-these-findings-and-how-do-you-translate-the-results-into-medical-cardiology-practice 2019-04-02T00:49:34+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-cite-specific-patient-types-where-you-are-strongly-inclined-to-use-a-pcsk9-inhibitor-because-achieving-both-significant-percentage-based-reductions-in-ldl-c-level-as-well-as-achieving-an-ldl-c-level-70mg/dl-are-of-critical-import 2019-04-08T05:11:19+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/do-you-use-different-ldl-c-levels-in-persons-with-diabetes-to-justify-initiation-of-pcsk9-inhibitors-is-the-presence-of-acs-required-or-symptomatic-ascvd-required-to-triage-them-into-pcsk9-based-treatment 2019-04-02T00:47:56+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-light-of-the-effectiveness-and-safety-in-post-acs-patients-of-the-ultra-low-levels-of-ldl-c-achieved-in-the-odyssey-outcomes-and-fourier-trials-how-has-that-shaped-your-clinical-perspective-on-the-role-of-pcsk9-inhibitors-in-high-risk 2019-04-08T05:14:05+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/based-on-the-odyssey-outcomes-trial-specifically-the-low-ldl-c-levels-achieved-without-adverse-consequences-what-target-level-of-ldl-c-do-you-recommend-in-medically-managed-patients-with-moderate-to-high-risk-features-of-ascvd 2019-04-02T00:49:40+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/given-that-odyssey-outcomes-has-shown-not-only-reduction-in-cv-events-but-also-a-reduction-in-associated-all-cause-mortality-what-is-the-role-of-pcsk9-inhibitors-in-diabetes-patients-with-a-prior-acs-event 2019-04-02T00:54:19+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/you-have-noted-that-70-mg/dl-is-the-aha-guideline-threshold-for-the-ldl-c-level-in-high-risk-patients-but-when-in-your-view-is-more-aggressive-lowering-to-levels-such-as-those-observed-in-the-odyssey-outcomes-and-fourier-trials-justified 2019-04-02T00:48:38+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-drill-down-into-the-specific-results-of-the-odyssey-outcomes-trial-that-demonstrate-unique-significant-reductions-in-associated-all-cause-mortality-and-how-these-findings-might-be-relevant-to-the-interventional-cardiologist 2019-04-02T00:47:50+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/given-the-new-guidelines-price-reductions-and-the-reduction-in-associated-all-cause-mortality-reported-with-alirocumab-in-odyssey-outcomes-which-patients-should-now-be-embraced-as-plausible-candidates-for-pcsk9-mediated-cv-risk-reduction 2019-04-08T05:08:11+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-a-program-director-with-a-mandate-to-improve-quality-of-cv-care-how-do-you-see-role-of-pcsk9-inhibitors-in-subspecialty-groups-interventional-cardiologists-medical/preventive-cardiologists-lipidologists/ascvd-and-diabetes-specialists 2019-04-08T05:46:28+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-your-interventional-cardiology-practice-which-markers-of-risk-in-the-patient-who-has-undergone-a-pci-do-you-focus-on-to-promote-consideration-for-using-a-pcsk9-inhibitor 2019-04-02T00:32:31+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-medical-cardiologist-s-perspective-how-do-the-threshold-setting-targets-of-ldl-c-levels-of-70-mg/dl-apply-to-pcsk9-based-treatment-for-cv-risk-reduction-did-the-guidelines-emphasize-sufficiently-the-results-of-the-cv-outcome-trial 2019-04-08T05:47:04+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-should-the-threshold-of-70-mg/dl-identified-in-the-aha-guidelines-mean-to-the-medical-or-preventive-cardiologist-in-his/her-aspiration-to-optimize-cv-risk-reduction-in-high-risk-patients-with-a-history-of-acs-or-related-high-risk-fe 2019-04-08T05:09:47+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-has-our-knowledge-of-the-safety-and-efficacy-of-pcsck9-inhibitors-evolved-and-how-has-the-odyssey-outcomes-treat-to-target-trial-helped-us-translate-these-advances-into-the-front-lines-of-interventional-cardiology-practice 2019-04-08T05:35:04+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-have-we-learned-from-the-odyssey-outcomes-pharmacoeconomic-analysis-that-you-and-professor-deepak-bhatt-reported-at-the-aha-2018-meeting-and-what-are-the-implications-for-the-clinician-cardiologist-who-is-making-the-case-to-payors 2019-04-02T00:55:06+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-medicine-specialist-how-do-the-results-of-the-now-published-odyssey-outcomes-trial-and-related-trials-help-you-select-patients-for-pcsk9-mediated-ldl-c-reduction-and-what-targets-do-you-advocate 2019-04-08T05:18:13+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/you-have-introduced-the-concept-of-progressive-atherosclerotic-burden-to-characterize-the-multiplicity-of-biologic-metabolic-and-clinical-markers-in-a-cv-risk-profile-how-do-you-apply-this-aggregated-risk-to-patient-selection-for-pcsk9-i 2019-04-02T00:54:14+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/why-is-down-titration-from-a-high-intensity-statin-dose-potentially-problematic-and-what-are-the-pragmatic-implications-as-they-relate-to-pcsk9-inhibitor-use-in-patients-who-cannot-achieve-optimal-cv-reduction-with-statin-therapy 2019-04-02T00:48:24+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-large-is-the-subgroup-of-diabetic-patients-who-you-feel-are-likely-to-appropriate-candidates-for-pcsk9-inhibition-to-optimize-cv-risk-reduction-and-how-does-the-lack-of-a-safety-signal-influence-your-recommendations-for-this-group 2019-04-02T00:33:27+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/with-respect-to-patients-with-hefh-and-homozygous-fh-who-are-challenged-with-lifelong-cv-disease-risk-burden-due-to-genetic-risk-what-role-do-you-believe-pcsk9-inhibitors-should-play-especially-in-younger-patient-populations 2019-04-02T00:33:39+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-discuss-the-reductions-in-mace-events-reported-in-the-pcsk9-outcome-trials-and-how-they-shape-the-benefit/safety-equation-for-the-use-of-alirocumab-and-evolocumab-in-high-risk-patients-including-diabetics-for-secondary-prevention 2019-04-02T00:34:20+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/which-patient-subgroups-that-based-on-the-odyssey-outcomes-trial-could-benefit-significantly-from-a-pcsk9-inhibitor-in-your-observation-are-not-getting-treatment-consistently-enough-i-e-are-being-under-treated-with-these-agents 2019-04-02T00:31:07+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/given-what-we-know-about-the-safety-of-pcsk9-inhibitors-and-the-risk-of-recurrent-events-in-patients-who-have-experienced-an-acs 2019-04-08T05:12:42+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-does-the-pharmacoeconomic-landscape-currently-look-like-for-pcsk9-inhibition-especially-in-light-of-the-recent-price-reductions-for-alirocumab-and-evolocumab 2019-04-08T05:42:04+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-have-the-trifecta-of-recent-developments-associated-all-cause-mortality-reduction-reported-in-odyssey-outcomes-price-reduction-of-pcsk9-inhibitors-and-new-aha-guidelines-affected-your-approach-to-deploying-these-agents-at-the-front-l 2019-04-02T00:48:30+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-the-type-2-diabetes-population-that-you-manage-in-your-what-percentage-of-patients-do-you-estimate-do-not-achieve-risk-appropriate-ldl-c-for-any-number-of-reasons-is-it-as-high-as-10-as-reported-in-by-some-diabetes-experts 2019-04-02T00:54:23+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-has-been-your-experience-with-respect-to-patient-satisfaction-discontinuation-rates-and-toleration-of-this-injection-based-approach-to-ldl-c-management 2019-04-02T00:32:44+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-is-the-unmet-need-for-residual-cv-risk-reduction-in-post-acs-patients-with-t2d-in-your-role-as-a-member-of-the-ldl-guideline-group-for-aace-what-were-the-implications-of-treating-diabetic-patients-with-so-called-extreme-risk 2019-04-08T05:16:17+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/a-confluence-of-events-has-reshaped-the-accessibility-evidence-basis-and-actionability-profile-for-pcsk9-inhibitors-as-an-atherosclerosis-specialist-how-have-these-developments-changed-the-equation-and-shaped-your-approach-to-cv-risk-red 2019-04-08T05:04:21+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-are-the-risks-of-failing-to-lower-ldl-c-levels-to-aha-or-esc-guideline-mandated-thresholds 2019-04-02T00:31:33+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-provide-some-specific-examples-of-patients-in-your-general-cardiology-practice-in-whom-you-have-prescribed-pcsk9-inhibitors-and-your-rationale-and-the-evidentiary-basis-for-doing-so-when-does-statin-intolerance-play-a-role 2019-04-08T05:43:27+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-are-the-specific-patient-types-that-you-manage-in-your-lipid-focused-practice-and-which-are-referred-to-you-for-potential-intervention-with-a-pcsk9-inhibitor-why-are-these-patients-being-referred-to-you-for-pcsk9-mediated-ldl-c-redu 2019-04-08T05:20:09+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/do-you-have-any-safety-concerns-about-driving-ldl-c-levels-to-less-than-50-mg/dl-with-pcsk9-inhibitors 2019-04-08T05:29:43+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/since-the-overwhelming-majority-of-post-acs-patients-in-odyssey-outcomes-had-pci-as-part-of-their-acs-management-what-have-we-learned-about-the-safety-and-efficacy-of-alirocumab-in-this-stent-rich-population-of-high-risk-patients 2019-04-02T00:34:33+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-are-the-current-challenges-and-protocols-in-europe-for-making-pcsk9-inhibitors-an-easily-reimbursable-mainstream-approach-to-managing-patients-with-require-secondary-prevention-for-their-high-risk-ascvd 2019-04-08T05:02:46+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-other-markers-besides-ldl-c-levels-do-you-believe-we-should-consider-to-refine-cv-risk-stratification 2019-04-02T00:31:46+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-should-the-fact-that-cv-risk-is-not-binary-but-progressive-influence-the-decision-to-use-a-pcsk9-inhibitor 2019-04-02T00:31:54+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/although-70-mg/dl-is-the-target-threshold-identified-by-both-esc-and-aha-should-the-interventionalist-in-a-patient-who-has-just-undergone-a-pci-and-has-an-ldl-c-of-69-mg/dl-be-considered-adequately-cv-risk-mitigated 2019-04-02T00:31:50+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-discuss-the-importance-of-the-two-principal-psck9-cv-outcome-trials-odyssey-outcomes-and-fourier-and-how-they-are-similar-and-in-what-ways-they-are-different-what-are-the-implications-for-the-patient-with-t2d-and-ascvd 2019-04-02T00:34:13+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-light-of-the-recent-results-showing-a-reduction-in-associated-all-cause-mortality-in-the-odyssey-outcomes-trial-which-patients-deserve-our-greatest-attention-to-optimize-the-translational-impact-of-this-study 2019-04-02T00:32:54+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/based-on-odyssey-outcomes-for-which-biological/metabolic-risk-markers-do-you-feel-that-cardiologists-and-atherosclerosis-specialists-should-strive-to-achieve-ldl-c-levels-even-more-aggressive-than-those-identified-in-the-aha-guidelines 2019-04-02T00:54:28+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-lipid-specialist-s-perspective-do-the-results-from-the-odyssey-outcomes-trial-suggest-the-need-to-be-more-focused-on-achieving-absolute-target-levels-of-ldl-c-or-relative-percentage-reductions-in-ldl-c-levels 2019-04-02T00:55:04+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-which-of-your-patients-with-fh-do-you-feel-psck9-inhibitors-will-become-foundational-agents-in-conjunction-with-statins-when-tolerated 2019-04-08T05:25:05+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-have-the-2016-canadian-cardiovascular-society-guidelines-for-ldl-c-reduction-positioned-their-recommendations-for-ldl-c-target-goals-and-how-do-you-anticipate-these-might-change-in-the-future-based-on-the-odyssey-outcomes-and-fourier 2019-04-02T00:54:12+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-have-the-results-of-odyssey-outcomes-especially-as-they-relate-to-progressive-cv-risk-reductions-in-patients-with-high-ldl-c-levels-who-achieve-target-levels-of-50-mg/dl-or-less-support-the-treat-to-target-approach-to-lipid-managemen 2019-04-08T05:44:24+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-medical-cardiologist-and-acs-expert-perspective-can-you-identify-which-patients-should-undergo-consideration-for-pcsk9-mediated-ldl-c-reduction-and-what-risk-factors-should-encourage-cv-specialists-to-pursue-pcsk9-based-therapies 2019-04-02T00:48:28+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-stratify-your-patients-with-known-ascvd-to-determine-their-eligibility-for-pcsk9-inhibitors-and-are-there-some-patients-that-you-would-characterize-as-ultra-high-risk-and-therefore-requiring-ldl-c-lowering-to-less-than-70-mg/d 2019-04-02T00:49:32+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/given-the-new-aha-guidelines-and-the-anticipation-of-new-esc-guidelines-in-2019-what-is-your-view-about-ldl-c-level-target-thresholds-vs-degree-of-ldl-c-reduction-what-level-do-you-consider-optimal-in-high-risk-patients-with-progressive- 2019-04-08T05:02:06+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-your-lipid-practice-which-patients-with-ascvd-do-you-prioritize-for-pcsk9-mediated-lowering-of-ldl-c-based-on-odyssey-outcomes-what-do-we-know-about-the-subgroup-of-post-acs-patients-who-benefited-most-from-alirocumab 2019-04-08T05:25:40+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/odyssey-outcomes-reports-that-post-acs-patients-with-starting-ldl-c-levels-greater-than-100-mg/dl-benefited-most-but-you-have-noted-the-importance-of-assessing-aggregate-risk-when-identifying-triggers-for-pcsk9-based-therapy-can-you-disc 2019-04-02T00:48:36+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-are-the-principal-concerns-related-to-cv-risk-reduction-in-patients-with-t2d-and-where-does-ldl-c-lowering-with-pcsk9-inhibitors-fit-into-the-clinical-strategy 2019-04-02T00:35:33+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-percentage-of-patients-have-statin-muscle-intolerance-based-on-the-criteria-you-and-your-colleagues-have-developed-why-is-there-a-disconnect-between-the-prevalence-of-statin-muscle-intolerance-vs-the-results-reported-in-major-trials 2019-04-02T00:48:22+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-medical-cardiologist-s-perspective-why-is-the-mandate-to-lower-ldl-c-level-so-important-for-reducing-cv-risk-how-low-do-recommend-lowering-the-ldl-c-level-where-do-the-pcsk9-inhibitors-fit-into-the-overall-sequencing-strategy 2019-04-02T00:35:36+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/at-your-institution-do-you-experience-any-significant-barriers-to-having-prescriptions-authorized-for-alirocumab-or-evolocumab-and-how-have-the-price-reductions-affected-either-your-perception-of-access-to-and/or-reimbursement-for-these- 2019-04-02T00:35:27+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-recommend-that-clinicians-directly-and-immediately-apply-the-results-of-the-cv-outcome-trials-with-alirocumab-and-evolocumab-directly-to-the-front-lines-of-medical-cardiology-practice 2019-04-02T00:32:42+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/which-patients-in-your-view-based-on-the-odyssey-outcomes-and-fourier-trials-do-you-want-to-drive-below-the-ldl-c-threshold-of-70-mg/dl-what-is-your-rationale-and-how-do-you-select-your-patients-and-achieve-your-targets-in-the-real-world 2019-04-08T05:10:26+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-have-recent-pcsk9-trials-affected-your-position-on-the-role-of-intensifying-ldl-c-reductions-to-new-target-levels-and-how-are-they-likely-to-affect-future-global/esc-2019-guidelines-for-ldl-mediated-cv-risk-reduction 2019-04-08T05:13:16+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-do-we-know-from-the-sub-analyses-of-the-odyssey-outcomes-trial-that-looked-at-patients-with-ldl-c-levels-below-50-mg/dl-which-of-these-based-on-baseline-ldl-c-levels-derived-disproportionate-mortality-reduction-benefit-from-alirocum 2019-04-02T00:33:24+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/why-are-patients-who-should-clearly-be-on-a-pcsk9-inhibitor-not-being-treated-in-the-primary-cardiology-setting-but-rather-seeking-and-obtaining-this-treatment-in-the-lipid-clinic-environment 2019-04-02T00:48:34+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-approach-the-diabetic-patient-who-also-has-a-constellation-of-multiple-high-risk-features-above-and-beyond-the-underlay-of-diabetes-what-is-the-relative-and-absolute-benefit-of-employing-pcsk9-inhibitors-in-this-patient-popula 2019-04-02T00:48:21+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/with-the-results-of-odyssey-outcomes-and-the-more-attractive-pricing-for-pcsk9-inhibitors-how-do-you-now-see-the-landscape-for-this-therapy-especially-in-the-context-of-the-lipid-medicine/atherosclerosis-specialist-and-the-preventive-car 2019-04-02T00:54:10+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/should-lipidologists-consider-other-markers-such-as-apob-as-well-as-ldl-c-for-reducing-cv-risk-in-diabetes-and-hypertriglyceridemia 2019-04-02T00:29:57+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/have-studies-been-done-looking-at-pcsk9-inhibitors-as-monotherapy-in-post-acs-patients-with-elevated-ldl-c-levels 2019-04-02T00:32:38+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/given-the-reduction-in-both-cv-outcomes-and-associated-all-cause-mortality-are-the-ldl-c-thresholds-currently-recommended-by-the-aha-and-esc-low-enough-and-what-are-the-implications-for-pcsk9-mediated-cv-risk-reduction 2019-04-02T00:36:48+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-did-we-learn-specifically-about-the-population-of-patients-with-post-acs-and-t2d-who-were-treated-with-alirocumab-in-the-odyssey-outcomes-trial 2019-04-08T05:39:06+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/assuming-the-community-cardiologist-is-able-to-obtain-reimbursement-for-pcsk9-inhibitors-in-what-segment-of-your-patient-population-do-you-think-this-therapy-is-most-under-utilized-how-do-price-reductions-for-these-agents-affect-your-app 2019-04-08T05:31:29+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-a-high-risk-patient-who-has-undergone-multiple-stent-procedures-what-criteria-do-you-prioritize-for-initiating-a-pcsk9-inhibitor-in-the-setting-of-pci-and-what-absolute-ldl-c-targets-are-in-your-cross-hairs-based-on-the-odyssey-outcom 2019-04-02T00:47:41+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/since-esc-and-acc/aha-are-examining-hard-ldl-c-targets-for-patients-at-risk-for-ascvd-how-does-odyssey-outcomes-help-inform-cardiologists-about-the-rationale-for-pcsk9-mediated-lowering-to-achieve-ultra-low-levels-i-e-50-mg/dl-of-ldl-c 2019-04-02T00:47:54+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-an-interventional-cardiologist-in-the-uk-what-do-the-results-from-the-odyssey-outcomes-trial-and-price-reductions-mean-to-the-clinician-at-the-front-lines-of-cardiology-care-as-far-as-access-to-and-triggers-for-deploying-a-pcsk9-inhib 2019-04-02T00:31:52+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/based-on-the-odyssey-outcomes-trial-which-enrolled-primarily-patients-with-post-acs-which-subset-of-patients-managed-in-a-medical-cardiology-practice-should-be-thoroughly-evaluated-for-cv-risk-reduction-benefits-accruing-to-pcsk9-inhibit 2019-04-02T00:32:33+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/to-what-degree-have-you-observed-statin-intolerance-or-resistance-in-patients-with-high-risk-cad-what-protocol-do-you-employ-to-mitigate-and/or-manage-statin-intolerance-where-does-the-pcsk9-inhibitor-fit-into-your-sequencing-strategy 2019-04-02T00:30:51+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-lipid-specialist-perspective-how-do-you-navigate-the-risk-territory-of-ldl-c-levels-70-mg/dl-with-pcsk9-inhibitors-and-in-which-patient-subgroups-do-these-agents-offer-unique-outcome-related-benefits 2019-04-08T05:17:36+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-help-us-de-convolute-what-is-more-important-a-the-absolute-level-of-ldl-c-level-attained-among-patients-in-the-odyssey-outcomes-trial-or-b-the-delta-i-e-the-relative-change-from-baseline-ldl-c-level-at-time-of-entry-into-the-tria 2019-04-02T00:47:49+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-should-the-lipid-and-atherosclerosis-disease-specialist-interpret-the-esc-and-aha-guideline-threshold-of-70-mg/dl-ldl-c-level-and-determine-whether-even-lower-levels-are-even-better-to-mitigate-residual-cv-risk 2019-04-08T05:37:40+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-the-cost-and-institutional-barriers-to-deploying-pcsk9-inhibitors-become-less-onerous-which-patients-in-a-medical-cardiology-practice-represent-the-most-attractive-candidates-for-these-agents-and-their-profound-ldl-c-lowering-effects 2019-04-02T00:32:46+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-view-the-lack-of-current-safety-signals-encountered-in-cv-outcome-trials-with-pcsk9-inhibitors-what-are-the-implications-for-lifelong-use-of-these-agents 2019-04-08T05:47:49+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-lipid-medicine-and-preventive-cardiovascular-perspective-how-do-you-triage-the-diabetic-patient-with-acs-into-a-pcsk9-based-treatment-strategy-for-ldl-c-reduction 2019-04-08T05:40:43+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-specialist-especially-in-light-of-the-associated-all-cause-mortality-reductions-reported-in-odyssey-outcomes-how-should-the-clinician-be-thinking-about-pcsk9-inhibitors-as-a-tool-in-their-day-to-day-practi 2019-04-08T05:37:02+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-a-patient-centric-clinical-profile-perspective-which-high-risk-burden-patient-populations-do-you-as-an-atherosclerosis-specialist-single-out-for-pcsk9-mediated-ldl-c-reduction 2019-04-08T05:06:16+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-an-ic-you-are-seeing-post-acs/post-pci-patients-whose-atherosclerotic-disease-burden-is-exceptional-and-potentially-amenable-to-pcsk9-mediated-cv-risk-reduction-where-is-your-specific-focus-for-using-these-agents-in-this-population 2019-04-02T00:31:36+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-the-perspective-of-a-lipid-and-atherosclerosis-specialist-assuming-that-the-barriers-to-pcsk9-inhibitors-are-reduced-which-patients-at-risk-for-or-with-confirmed-ascvd-represent-the-best-risk-directed-candidates-for-ldl-c-lowering 2019-04-08T05:12:00+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-describe-the-actual-clinical-phenotypes-actual-patients-referred-to-you-by-interventional-or-medical-cardiologists-in-which-pcsk9-inhibition-would-represent-a-foundational-approach-to-reduction-of-residual-cv-risk-burden 2019-04-02T00:37:00+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-is-your-experience-deploying-pcsk9-inhibitors-in-the-clinic-and-what-are-the-most-reliable-and-actionable-triggers-for-deploying-this-program-for-cv-risk-reduction-and-predictably-achieving-reimbursement-and-payor-support-for-this-t 2019-04-08T05:42:46+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-interpret-the-reduction-in-associated-overall-mortality-seen-with-alirocumab-in-the-odyssey-outcome-trial-as-compared-to-the-lack-of-such-findings-at-least-prior-to-results-for-the-extension-phase-in-fourier-for-the-evolocumab 2019-04-08T05:32:56+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/since-both-pcsk9-outcome-trials-demonstrated-impressive-safety-when-ldl-c-levels-are-lowered-into-ranges-much-lower-than-70-mg/dl-what-should-be-the-approach-of-the-interventional-and-medical-cardiologist-to-achieving-ldl-c-levels-in-thi 2019-04-02T00:32:48+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/do-you-see-safety-signals-associated-with-ultra-aggressive-ldl-c-lowering-and-what-is-the-role-of-pad-as-a-risk-factor-guiding-ldl-c-reduction 2019-04-02T00:54:16+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/can-you-discuss-the-esc-guidelines-for-ldl-c-targets-and-the-recent-aha-guidelines-designating-a-target-threshold-of-70-mg/dl-is-this-low-enough-what-is-your-recommendation-for-pcsk9-inhibition-in-the-high-risk-acs-patient-who-has-underg 2019-04-02T00:32:36+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/professor-bhatt-you-presented-the-pharmacoeconomic-in-trial-analysis-for-alirocumab-based-on-the-odyssey-outcomes-trial-can-you-discuss-the-clinical-implications-of-your-analysis-and-how-reduced-costs-for-alirocumab-will-affect-ic-practi 2019-04-16T18:09:42+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/are-you-finding-it-easier-to-get-authorization-for-reimbursement-and-approval-of-pcsk9-inhibitors-now-that-prices-have-come-down-and-we-have-seen-clear-outcome-benefits-in-both-major-trials 2019-04-08T05:28:59+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-is-the-current-unmet-need-for-cv-risk-reduction-in-general-beyond-ldl-c-level-lowering 2019-04-08T05:03:30+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/where-did-the-70-mg/dl-ldl-c-target-goal-come-from-why-wasn-t-it-set-lower-in-the-guidelines-from-the-outset-for-patients-with-acs 2019-04-02T00:31:09+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/considering-that-younger-persons-are-vulnerable-to-carrying-a-lifelong-atherosclerosis-burden-when-their-ldl-c-levels-are-elevated-how-to-do-approach-them-management-wise 2019-04-08T05:23:47+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-has-been-your-clinical-experience-with-respect-to-the-comparative-toleration-of-statins-vs-pcsk9-inhibitors 2019-04-02T00:33:46+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/which-patients-in-your-view-are-not-candidates-for-pcsk9-inhibition 2019-04-08T05:21:02+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-a-lead-investigator-for-both-fh-and-ascvd-focused-trials-evaluating-pcsk9-inhibitors-what-is-your-interpretation-of-the-data-confirming-regimen-adherence-and-compliance-with-these-injectable-agents 2019-04-02T00:34:24+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-identify-progressing-patients-with-high-cv-risk-in-whom-pcsk9-therapy-represents-a-game-changing-strategy 2019-04-02T00:31:42+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/although-the-aha-guidelines-emphasize-cv-risk-and-mortality-reductions-with-statins-odyssey-outcomes-provides-comparable-evidence-for-alirocumab-how-compelling-is-the-evidence-for-pcsk9-inhibition-as-a-mediator-of-cv-risk-and-mortality-r 2019-04-02T00:31:38+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-the-lipid-clinic-setting-in-patients-you-have-treated-with-pcsk9-inhibitors-what-are-you-finding-as-far-as-regimen-adherence-toleration-and-patient-engagement/satisfaction-with-these-injectable-strategies 2019-04-08T05:19:25+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-see-the-benefit/safety-risk-equation-shaping-up-for-pcsk9-inhibitors-based-on-the-fourier-and-most-recently-the-odyssey-outcomes-trial 2019-04-02T00:49:31+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-your-perspective-as-a-medical-cardiologist-what-impact-should-the-reductions-in-associated-overall-mortality-reported-with-alirocumab-in-the-odyssey-outcomes-trial-have-on-selecting-a-pcsk9-inhibitor 2019-04-02T00:33:44+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/given-the-results-of-odyssey-fourier-and-others-as-a-lipid/atherosclerosis-specialist-what-is-your-take-home-about-what-the-appetite-should-be-for-using-pcsk9-inhibitors-to-lower-ldl-c-levels-beyond-esc-and-aha-recommended-thresholds-of- 2019-04-08T05:24:28+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-patients-requiring-down-titration-of-their-statins-due-to-muscle-discomfort/pain-what-is-the-trigger-point-for-moving-beyond-statins-to-consider-pcsk9-inhibitors 2019-04-08T05:14:46+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/with-the-odyssey-outcomes-trial-s-favorable-pharmacoeconomic-analysis-now-established-and-a-reduction-in-all-cause-mortality-with-alirocumab-where-do-you-see-the-evidence-based-opportunities-for-these-agents-in-your-practice-setting 2019-04-08T05:40:00+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-a-medical-cardiologist-treating-patients-for-secondary-prevention-of-ascvd-can-you-share-with-us-the-outcomes-and-disease-course-of-patients-you-have-managed-with-pcsk9-inhibitors-has-the-cost-reductions-affected-your-appetite-for-the 2019-04-08T05:45:54+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/does-the-presence-of-a-stent-in-the-setting-of-acs-color-your-approach-to-the-degree-of-ldl-c-reduction-you-would-pursue 2019-04-08T05:01:16+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-the-setting-of-secondary-prevention-for-patients-with-diabetes-the-role-of-ldl-c-has-special-significance-how-do-you-view-the-importance-for-the-of-pcsk9-inhibitors-therefore-specifically-for-reducing-residual-cv-risk-in-the-t2d-popul 2019-04-02T00:54:21+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-ldl-c-target-goals-should-a-consulting-or-treating-medical-cardiologist-recommend-for-patients-with-type-2-diabetes-with-a-known-acs-event-vs-diabetes-alone-as-a-risk-factor 2019-04-02T00:55:02+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-the-setting-of-a-medical-cardiology-practice-to-what-extent-is-statin-induced-muscle-intolerance-an-important-cause-of-poor-statin-adherence-increased-healthcare-costs-and-increased-cardiac-event-rates 2019-04-02T00:48:19+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/based-on-the-odyssey-outcomes-and-fourier-trials-which-patient-populations-including-individuals-with-t2d-do-you-believe-should-be-targeted-for-pcsk9-inhibitors 2019-04-02T00:35:40+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/which-diabetic-patients-in-particular-should-be-prioritized-for-pcsk9-mediated-cv-risk-reduction 2019-04-02T00:35:42+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/when-is-70-mg/dl-not-good-enough-is-this-a-threshold-what-clinical-factors-suggest-lower-targets-are-better-what-is-happening-at-the-vascular-biology-level 2019-04-02T00:47:47+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/based-on-odyssey-outcomes-and-fourier-what-are-the-findings-and/or-biologic-risk-features-lp-a-for-example-in-patients-managed-in-an-interventional-cardiology-setting-that-would-make-you-advocate-for-the-use-of-pcsk9-inhibitors 2019-04-02T00:47:52+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-should-the-ideal-target-ldl-c-be-in-the-type-2-diabetes-population-and-what-is-the-advantage-of-the-treat-to-target-strategy-employed-in-odyssey-outcomes-and-what-did-we-learn-about-associated-all-cause-mortality-with-alirocumab-in- 2019-04-02T00:34:18+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-vigorous-should-we-be-in-trying-to-lower-ldl-c-in-patients-who-have-statin-intolerance-what-is-the-role-of-combined-so-called-backbone-statin-treatment-plus-pcsk9-inhibitor-therapy 2019-04-08T05:38:18+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-the-view-of-an-interventional-cardiologist-and-a-lipid-medicine/atherosclerosis-specialist-can-you-discuss-what-ldl-c-thresholds-vs-clinical-burden/clinical-history-thresholds-are-important-for-patient-selection-for-pcsk9-based-risk 2019-04-02T00:31:40+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-did-odyssey-outcomes-and-fourier-teach-us-about-high-risk-patients-with-diabetes-and-the-relative-favorability-of-their-responses-to-ldl-c-lowering-with-pcsk9-inhibitors 2019-04-02T00:54:06+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-should-the-2018-aha-guidelines-for-ldl-c-that-specify-target-levels-for-high-risk-patients-impact-our-approach-to-selecting-therapies-including-pcsk9-inhibitors-that-have-the-potential-to-lower-ldl-c-to-levels-far-lower-than-those-re 2019-04-08T05:06:54+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-change-in-practice-based-on-the-all-cause-mortality-reduction-reported-in-odyssey-outcomes-do-you-believe-is-warranted-especially-as-these-results-might-impact-the-ldl-c-level-that-should-be-targeted-and-the-duration-of-therapy 2019-04-08T05:27:04+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/as-the-director-of-the-center-for-cardiovascular-disease-prevention-what-patient-types-on-the-risk-landscape-of-ascvd-do-you-believe-deserve-special-attention-because-they-are-likely-to-be-eligible-candidates-for-pcsk9-mediated-ldl-c-red 2019-04-02T00:54:26+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/in-your-framing-of-aggregate-ascvd-risk-as-a-stimulant-to-extremely-aggressive-ldl-c-lowering-what-clinical-signature-should-compel-the-general-cardiologist-to-translate-the-results-with-alirocumab-in-odyssey-outcomes-to-the-front-lines 2019-04-08T05:34:26+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/how-do-you-approach-younger-patients-with-known-advanced-subclinical-atherosclerosis 2019-04-08T05:08:57+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/assuming-optimization-of-patient-outcomes-rather-than-cost-is-the-primary-driver-governing-use-of-pcsk9-inhibitors-which-patients-in-a-medical-cardiology-practice-would-you-single-out-for-this-therapy-and-to-achieve-what-ldl-c-target-lev 2019-04-08T05:30:41+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/what-is-the-rationale-for-a-new-category-called-extreme-risk-introduced-by-aace-in-which-they-designate-a-threshold-ldl-c-target-of-55-mg/dl 2019-04-08T05:21:59+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/ic-and-lipid-specialists-are-challenged-to-maximize-cv-risk-reduction-in-high-risk-populations-how-should-they-approach-the-70-mg/dl-ldl-c-target-identified-in-the-aha-guidelines-and-when-is-the-30-mg/dl-70-mg/dl-even-more-desirable 2019-04-02T00:31:44+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/interventional-cardiologists-have-a-strong-incentive-to-use-pcsk9-inhibitors-in-many-high-risk-patients-but-real-world-factors-such-as-cost-can-present-barriers-to-optimizing-cv-risk-prevention-can-you-discuss-this-and-its-relevance-to-t 2019-04-02T00:47:37+0000 weekly 0.8 https://9690e.iqanda-cme.com/videos/from-the-specific-vantage-point-of-the-interventional-cardiologist-based-on-the-results-of-the-odyssey-outcomes-trial-which-patients-who-have-undergone-pci-do-you-believe-are-the-best-candidates-for-pcsk9-therapy 2019-04-02T00:47:45+0000 weekly 0.8 https://9690e.iqanda-cme.com/courses/iqanda-pcsk9-cardiovascular-medicine-intelligence-zone 2023-04-14T03:40:13+0000 weekly 0.8 https://9690e.iqanda-cme.com/flexpaper/the-odyssey-outcomes-trial-topline-results-alirocumab-in-patients-after-acute-coronary-syndrome 2019-03-28T01:13:28+0000 weekly 0.8 https://9690e.iqanda-cme.com/flexpaper/applicability-and-cost-implications-for-pcsk9-inhibitors-based-on-the-odyssey-outcomes-trial 2019-03-28T01:12:45+0000 weekly 0.8 https://9690e.iqanda-cme.com/flexpaper/infographic-nla-expert-panel-pcsk9-recommendations 2019-03-28T01:12:00+0000 weekly 0.8 https://9690e.iqanda-cme.com/flexpaper/2016-esc/eas-guidelines-for-the-management-of-dyslipidaemias 2019-03-28T01:12:58+0000 weekly 0.8 https://9690e.iqanda-cme.com/flexpaper/nla-expert-panel-pcsk9-recommendations 2019-03-28T01:12:15+0000 weekly 0.8 https://9690e.iqanda-cme.com/flexpaper/2018-aha/acc-guideline-on-the-management-of-blood-cholesterol 2019-03-28T01:13:14+0000 weekly 0.8 https://9690e.iqanda-cme.com/flexpaper/pooled-analysis-of-10-odyssey-trials-comparing-reductions-in-atherogenic-lipids-and-major-cv-events 2019-03-28T01:12:29+0000 weekly 0.8 https://9690e.iqanda-cme.com/flexpaper/program-agenda-and-complete-faq-list 2019-04-02T20:51:32+0000 weekly 0.8